CellaVision AB (publ) (CEVI) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you very much. And thank you very much out there for dialing in for Cellevision's quarterly report, Q4 2025, which obviously also includes the consolidated results from the entire 2025. A lot of good things have happened, and first of all, I want to formally welcome our newly appointed CFO, Monika Jönsson, who is with me today to participate and, of course, explain our business. Monika has been with us since autumn, and she was formally appointed CFO with Cellevision on December 12th. So that was the first good news. Hopping into the quarter in brief, the Q4 in brief, we have entitled our quarterly report as a solid quarter driven by strong performance in Americas. So it's particularly in Americas. However, we also see a pretty strong performance in EMEA, while the quarter has been somewhat soft in APAC. And we will unfold that throughout today's call. We landed the quarter with net sales that increased by 5.6% to a revenue stream of 197 million sec, which translate into an organic growth of 12.2% given our headwind on the FX of minus 6.6%. So double-digit growth throughout this quarter. This translate into an EBITDA contribution of 65 million sec, equivalent to 33 percentage points. In terms of the business, we will go into the business and explain both our P&L, our regional split, give some highlights there. and of course also cut it across the different product families. But I also want to give a little bit of insights as to our progress on our strategic direction. We accomplished a key milestone by getting CE Mark for our new applications for bone marrow aspirates. And so this is a Class C product that is now registered according to the EU IVDR, which allows us to start launching the product this year, or pretty much in the quarter we're in. We can talk mor...